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Abstract
A functional sphingosine-1-phosphate (S1P) receptor antagonist specifically inhibited the egress of activated allospecific T
cells from draining popliteal lymph nodes in alloantigen-sensitised mice. The level of S1P receptor 1 (S1PR1) mRNA was
similarly reduced 1 and 3 days after mitogenic activation of T cells. However, the response of these cells to the S1PR1-
specific agonist SEW2871 was only reduced on the first day after T cell activation with normal receptor-mediated Akt-
phosphorylation restored by day 3. Longitudinal analysis of CD69 expression showed that almost all T cells expressed this
antigen on days 1 and 3 after activation. However, the absolute level of cell-surface expression of CD69 peaked on
undivided T cells and was then halved by each of the first 3 cycles of mitosis. CD69-specific small interfering RNA (siRNA)
reduced the maximal level of CD69 expression by undivided, mitogen-stimulated T cells. These cells retained their capacity
to phosphorylate Akt in response to stimulation with SEW2871. These data show that S1P receptors are involved in
controlling the egress of activated T cells from lymph nodes, and that S1PR1 function is regulated by the level of T cell
surface CD69. They suggest a potential for augmentation of this process to deplete alloreactive effector cells after organ
transplantation.
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Introduction
Immunosuppression produced by the inhibition of calcineurin
has greatly enhanced the success of allogeneic organ trans-
plantation. However, long-term administration of calcineurin
inhibitors can cause a range of morbidities. For this reason there
is a continuing pressure to develop new immunosuppressive drugs
which function through different pathways. One novel strategy for
the induction of immunosuppression involves inhibition of the
efflux of activated T cells from the lymphoid tissues [1].
Under normal conditions, naı¨ve T cells recirculate continually
through blood and lymphatic tissues. Homeostatic chemokines,
principally CCL19, CCL21 and CXCL12, drive entry into lymph
nodes by promoting firm adhesion of T cells to high endothelial
venules (HEV) followed by endothelial diapedesis [2]. These T
cells remain in normal lymph nodes for between 6 and 24 hours
before exiting via the cortical sinuses [3,4]. This egress is driven by
a positive concentration gradient of sphingosine-1-phosphate (S1P)
from the lymph node to lymph, which stimulates the T cell-surface
receptor S1PR1 [5,6]. This model of T cell egress is supported by
the action of the drug FTY720, which disrupts lymphocyte
recirculation by inhibiting the normal response to S1P by binding
S1PR1. This drug-receptor complex is then internalized and
targeted for ubiquitination and degradation rather than recycling
to the cell surface [7–9].
The drug FTY720, which is phosphorylated to FTY720-P in
vivo, was found to prevent allograft rejection as effectively as
calcineurin inhibitors [10,11]. However, clinical trials were
terminated as a consequence of adverse affects which, most
significantly, included brachycardia. More specific analogues of
FTY720 include AUY954 [1] and KRP-203 which is known to
extend cardiac allograft survival in rodents [12]. Although new
clinical trials are planned in transplantation, it is clear that our
fundamental knowledge of regulation of the efflux of activated T
cells from lymphoid tissues remains incomplete.
At the start of an adaptive immune response, only a small
proportion of the T cells retained within a particular node is
primed by TCR-specific interaction with antigen-presenting cells
bearing immunogenic MHC antigen-peptide complexes. These T
cells are triggered to proliferate and differentiate, generating
effector and memory cells. Evidence suggests that the first effector
T cells move into the circulation 3 days after the initial priming
event [5]. This correlates with the period required for re-
acquisition of the responsiveness to S1PR1 stimulation of activated
T cells within the node [5].
It has been suggested that an activation-induced increase in the
expression of S1PR1 and decrease in CCR7 are the most
important factors resulting in the reacquisition of S1PR1 signalling
and migration of effector T cells from lymph nodes [6]. However,
this model does not include the potential involvement of CD69.
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CD69 is a type II TM protein of the C-type lectin family [13] and
exists in its mature form in cells as a disulphide-linked dimer [14].
For a long time it was known simply as a marker that is
upregulated onto the surface of T cells within hours of cell
activation [15,16]. More recently however, data from several
studies have indicated an important role for the protein in the
regulation of immune cell trafficking. Transgenic overexpression
studies showed that CD69 inhibited thymocyte egress from the
thymus [17], knockout of CD69 was shown to prevent lymph node
shutdown [18] and adoptive transfer experiments with CD69-
negative cells showed it was involved in relocation of memory T
cells into the bone marrow compartment [19]. Immunoprecipi-
tation and crosslinking-reporter assays showing direct interaction
of CD69 with S1PR1 indicate a likely mechanism behind these
phenomena. CD69 can form a complex with S1PR1 in the plasma
membrane which leads to receptor internalization and degrada-
tion [18,20].
The magnitude and dynamics of CD69 expression by T cells
vary depending on the stimulus applied. For example, treatment
for 1 h with type 1 IFNs induces low level expression of cell-
surface CD69 [18,21], whilst mitogenic T cell activation induces
gene transcription leading to high level CD69 expression
[16,22]. These differences could be important for the control
of S1PR1 signalling and regulation of the egress of T cells from
lymph nodes.
The current study was designed to define roles played by the
regulation of S1P-mediated signalling in controlling the egress of
alloantigen-activated T cells from lymph nodes. An initial series
of experiments was performed in vivo to demonstrate the
potential of FTY720 to prevent the normal export of activated,
alloantigen-specific T cells from reactive murine lymph nodes.
Further experiments were performed in vitro to validate the
relationship between the level of human T cell-surface CD69
expression and the response of S1PR1.S1PR1 function was
tested using SEW2871 as an agonist, as the molecule has been
shown to be highly selective for that S1P receptor. GTPcS
binding assays using S1PR transfectants showed strong binding
and signalling activity of SEW2871 through S1PR1, but
a complete lack of activity of the ligand on S1PR2, 3,4 and
5 at a concentration of 10 mM [23].
Materials and Methods
Reagents
FTY720 (S) phosphate (FTY720-P) was purchased from Cam-
bridge Bioscience (Cambridge, UK). It was dissolved in ethanol at
1 mg/ml for storage at 220uC. On the day of use 1 mg/ml
FTY720-P was diluted to 100 mg/ml in sterile water with 2% b-
cyclodextrin (Sigma-Aldrich; Poole, UK) and then mixed
thoroughly. SEW2871 was purchased from Enzo Life Sciences
(Exeter, UK).
Animals and Procedures
Female BALB/c (H2d) and C57BL/6 (H2b) mice (6–8 weeks
old; Charles River, Margate, UK) were maintained under
pathogen-free conditions. All procedures were performed in
accordance with UK Home Office and EU Institutional Guide-
lines and within the parameters of current personal and project
licences.
C57BL/6 mouse footpad injections (on day zero) were
unilateral, subcutaneous, and comprised 56106 BALB/c spleno-
cytes suspended in 25 ml RPMI 1640 medium (Sigma-Aldrich).
Between days 2 and 5, some mice were injected daily,
intraperitoneally, with 100 ml 100 mg/ml FTY720-P or an equal
volume of drug vehicle. The mice were killed on day six and the
popliteal lymph nodes draining the injected footpads removed.
Cell suspensions were prepared from the nodes by pressing the
tissue through 70 mm cell strainers (BD Biosciences; Oxford, UK)
into RPMI 1640 medium. Popliteal lymph node-derived cells were
washed twice with RPMI 1640 medium before further use.
BALB/c splenocytes were prepared as follows. Spleens were
mechanically disrupted then the tissue forced through cell strainers
into RPMI 1640 medium. The cells were purified by density
centrifugation (Histopaque-1083; Sigma-Aldrich).
Enzyme-linked Immunosorbent Spot (ELISPOT) Assay
Ninetysix-well format Immobilon MultiScreen-P plates (Milli-
pore; Watford, UK) were coated with IFN-c capture antibody
[clone AN18] (Mabtech; SE-131 28 Nacka Strand, Sweden)
diluted into carbonate-bicarbonate buffer (Sigma-Aldrich) over-
night at 4uC. These plates were washed twice with PBS and
blocked with RPMI 1640 medium supplemented with 10%
FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin (all
Sigma-Aldrich) for 1 h at room temperature. Mixed leukocyte
reaction assays were then performed in each well by mixing
16104 C57BL/6 popliteal lymph node-derived cells with 26105
BALB/c splenocytes in a total volume of 200 ml RPMI 1640
culture medium containing 50 mM 2-mercaptoethanol (Sigma-
Aldrich). After incubation for 18 h at 37uC the cells were
discarded and the plates washed six times with PBS. A
biotinylated IFN-c detection antibody [clone R4–6A2] (Mab-
tech), diluted in PBS, was applied overnight at 4uC. The plates
were washed six times with PBS. The streptavidin-alkaline
phosphatase conjugate (Mabtech) was diluted in PBS and
applied for 1 h at room temperature. The plates were washed
another six times with PBS and 50 ml of BCIP/NBT liquid
substrate system for membranes (Sigma-Aldrich) was added to
each well. After development for 5 min at room temperature,
the reaction was stopped by removal of substrate and washing
with tap-water. Developed spots were enumerated using an
ELISPOT reader (AiD; Strassberg, Germany).
Cell Isolation, Culture and Activation
Total CD3+ T cells were derived from human peripheral blood
or platelet-depleted leukocyte cones (NHS Blood and Transplant
Service, UK). They were isolated using an erythrocyte-rosetting
negative-selection kit (StemCell Technologies; Grenoble, France)
and cell separation by centrifugation across Lympholyte H
(Cedarlane Laboratories; Ontario, Canada). T cells were cultured
in X-VIVO 15 medium (Lonza; Slough, UK) and activated with
Dynabeads Human T Activator CD3/CD28 (Life Technologies;
Paisley, UK), at a ratio of one bead per cell and a starting culture
density of 16106 cells per ml.
Antibodies, Cell Labelling and Flow Cytometry
For analysis of mouse cells, the antibodies were CD3 [clone
KT3] (AbD Serotec) and CXCR3 [clone 220803] (R&D Systems).
The antibodies used for human cells were S1PR1 [clone 218713]
(R&D Systems) and CD69 [clone FN50] (BD Biosciences). In
some cases T cells were labelled by incubation with 1 mM CFSE-
DA (carboxyfluorescein diacetate N-succinimidyl ester; Sigma-
Aldrich) for 5 min at 37uC in PBS +0.1% (v/v) FBS. They were
then chilled rapidly on ice and washed with cold RPMI 1640
before use. Data was acquired on a FACSCanto II instrument (BD
Biosciences) and analysis performed using FACSDiva 6.1.3 (BD
Biosciences) and FlowJo 7.6 (Treestar; Ashland, Oregon, USA)
software.
Regulation of S1PR1 Responsiveness by T Cell
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Real Time PCR
RNA was prepared from cell pellets using TRI Reagent (Sigma-
Aldrich). cDNA was synthesised from approximately 1 mg RNA
per sample using SuperScript III Reverse Transcriptase and
random hexamers as primers (Life Technologies). Expression of
S1PR1 was determined semi-quantitatively using a specific Taq-
Man Gene Expression assay (Hs00173499_m1), with 18S ribo-
somal RNA as the reference (Hs99999901_s1; both Applied
Biosystems, Life Technologies; Paisley, UK). The amplifications
were run on an ABI Prism 7000 instrument (Applied Biosystems).
Protein Assays
T cells were lysed in a buffer containing CelLytic M (Sigma-
Aldrich) + Mini Complete Protease Inhibitor cocktail (Roche;
Welwyn, UK) + Halt Phosphatase Inhibitor cocktail (Thermo
Fisher Scientific; Loughborough, UK). The concentration of
protein in cell lysates was determined by BCA assay (Thermo
Fisher Scientific). Equal masses of protein (routinely 10–50 mg)
were loaded into each lane of a single gel and subjected to 12%
resolving SDS-PAGE. Transfer to polyvinylidene difluoride
membrane (GE Healthcare; Little Chalfont, UK) was by wet
electroblotting. Membranes were blocked with 5% immunoglob-
ulin-depleted BSA (Sigma-Aldrich) for 1 h before immunoblotting.
The primary antibodies used were: phospho(S473)-Akt [clone
D9E] and pan Akt [clone C68E7] (both New England Biolabs;
Hitchin, UK). The secondary antibody was horseradish peroxi-
dase-conjugated anti-rabbit IgG (Sigma-Aldrich).
Phospho(S473)-Akt and total Akt were also detected using a cell-
based ELISA (R&D Systems). Approximately 10 000 T cells were
added to each well of a 96-well format plate (previously coated
with 10 mg/ml poly-lysine (Sigma-Aldrich) for 30 min) and left to
attach for 1 h. The cells were treated for the desired length of time
then fixed with 8% formaldehyde. Phospho(S473)-Akt and total
Akt were detected by double immunoenzymatic labelling. The
relative quantities of the proteins were deduced from the intensities
of spectrally distinct fluorescences associated with each target. The
detector was a Dynex MFX instrument (Worthing, UK) operating
with excitation and emission wavelengths of 540 nm and 600 nm
for phospho(S473)-Akt, and 360 nm and 450 nm for Akt.
Gene Knockdown
Resting T cells were transfected with 100 pmol siRNA per
million cells by electroporation (Nucleofector I instrument; Lonza).
For CD69 knockdown, an equimolar mixture of three 21
nucleotide duplexes (MISSION siRNA; Sigma-Aldrich) was used.
The single strand sequences were:
59 GAGUUAGAUGUUGGUACUA 39
59 CUACUCUUGCUGUCAUUGA 39
59 CUCUCAUUGCCUUAUCAGU 39
Figure 1. Activated T cells required S1P receptor signalling to exit lymph nodes. (A and B) C57BL/6 mice were injected i.p. with 100 ml of
100 mg/ml FTY720-P daily for two days, or left untreated. On day three, blood samples were taken from the tail vein and CD3-positive cells
enumerated by flow cytometry. (C-F) Mice were injected with BALB/c splenocytes into the footpad on day zero and treated with FTY720-P or vehicle
daily from days 2 to 5. On day six the popliteal lymph nodes were removed. (C) The nodes were disrupted and the total number of cells measured
using a haemocytometer. (D) Popliteal node-derived cells were mixed with BALB/c splenocytes in IFN-c cultured ELISPOT reactions. Data are
presented as the number of IFN-c spot-forming cells per 1000 popliteal node-derived cells. Points represent individual mice; 6 mice treated with
vehicle, 7 with FTY720-P. Horizontal lines are means of groups. (E) Popliteal node cells were stained with an anti-mouse CXCR3 monoclonal antibody
and analysed by flow cytometry. Flow histograms show representative staining of cells from one control mouse and one drug-treated mouse.
Numbers are the percentage of lymph node-derived cells that were CXCR3-positive. (F) Graph showing CXCR3 expression by popliteal node cells
derived from 3 control and 3 drug-treated mice. Points represent individual mice, horizontal lines are means of groups.
doi:10.1371/journal.pone.0045548.g001
Figure 2. S1PR1 expression by resting and activated T cells. T cells were negatively selected from human peripheral blood. T cells were left at
rest or stimulated for 1 or 3 days with mitogenic CD3/CD28 beads. The relative expression of mRNA encoding S1PR1 was determined in those cell
populations by semi-quantitative RT-PCR. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0045548.g002
Regulation of S1PR1 Responsiveness by T Cell
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Separately, as a control, cells were transfected with an equal
mass of MISSION siRNA Universal Negative Control 1 (Sigma-
Aldrich).
After transfection, the T cells were rested for about 5 h in X-
VIVO 15 before addition of Dynabeads Human T Activator
CD3/CD28 at a ratio of one bead per cell. 24 hours later the cells
were analysed directly for CD69 expression or viable cells were
sorted using a FACS Aria II (BD Biosciences) instrument for
phospho-protein analysis.
Statistics
Prism 4.0c (GraphPad Software; La Jolla, California, USA) was
used for statistical analyses. Comparisons between groups were
made using the Student’s t-test for unpaired data. P values #0.05
were considered significant.
Results
The Egress of Alloactivated T cells from Lymph Nodes is
Dependent on Intact S1P Receptor Signalling
An initial series of experiments demonstrated that unilateral foot
pad sensitisation of C57BL/6 mice with BALB/c splenocytes
produced a difference (P,0.01) in popliteal node cellularity after 6
days, with a mean of 2.016106 cells (s.e.m. 0.176106) recovered
from the sensitised side and 4.886105 (s.e.m. 2.926105) from the
uninvolved contralateral node (data not shown). Efficacy of the
drug FTY720-P in our animal model was tested by measuring the
effect of its administration on the frequency of peripheral blood
CD3+ cells. Daily dosing over two days resulted in a greater than
90% depletion of CD3+ cells from peripheral blood (Fig 1A and
B). A second series of experiments showed that the overall yield of
cells from the reactive popliteal node of sensitised animals was not
Figure 3. The capacity of S1PR1 to signal in T cells before and after cell activation. T cells were either left at rest or stimulated with CD3/
CD28 beads for 1, 3 or 6 days. (A) The cells were then treated for 10 minutes with either 10 mM SEW2871 or vehicle before being lysed. Akt
phosphorylated at residue serine 473 (pAkt) and total Akt were detected in cell lysates by western blotting. Blots are representative of those from
three independent experiments. (B) Cell-based ELISA was used to quantify the relative amounts of pAkt and Akt in each cell population before and
after cell stimulation with SEW2871. The relative amounts of pAkt in the samples were calculated by normalising the fluorescent signal value
corresponding to pAkt to that of total Akt in each experimental well. Graph shows means 6 s.e.m, n = 3 for each time point.
doi:10.1371/journal.pone.0045548.g003
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changed from control values by daily treatment with FTY720-P
(P.0.05; Fig 1C).
Measurement by ELISPOT of the frequency of IFN-c pro-
ducing, alloreactive T cells in the population recovered from
reactive popliteal lymph nodes showed a difference (Fig 1D;
P,0.01) between animals treated with the drug vehicle and
FTY720-P, with a mean 1.9-fold enrichment of these cells in nodes
from the drug treated animals. Analysis of the expression of the T
cell activation-associated chemokine receptor CXCR3 in the
popliteal node-derived cell population (Fig 1E) also showed a mean
1.9-fold enrichment of these cells in drug-treated animals (Fig 1F;
P,0.05).
T cell Activation is Associated with a Transient Loss in
S1PR1 Signalling Capacity
Longitudinal analysis of the expression of S1PR1 gene following
T cell activation by stimulation of CD3 and CD28 (Fig 2) showed
a marked reduction in transcription after 24 h; a similarly reduced
level of mRNA encoding this receptor was observed 3 days after T
cell activation.
To test for the presence of functional S1PR1 at the cell surface,
T cells were stimulated with the specific agonist SEW2871 and
activation of the downstream signalling component Akt measured.
When resting cells were stimulated with the specific agonist
SEW2871 there was rapid formation of the phosphoserine (473)
derivative of Akt (pAkt) (Fig 3A). Stimulation of T cells with this
agonist 24 h after the activation of T cells did not increase the level
of pAkt. However, an increased level of pAkt was observed when
T cells were stimulated with SEW2871 on either day 3 or 6 after
mitogenic activation. Additionally, Cell-based ELISA was used to
quantify the relative amounts of pAkt and Akt in each cell
population before and after cell stimulation with SEW2871. Data
from three independent donors (Fig 3B) show that the transient
reduction in S1PR1-mediated intracellular signalling was only
apparent 1 day after T cell activation.
Analysis of CD69 Expression Following T cell Activation
Flow cytometric analysis of human T cell surface expression of
CD69 showed that almost no resting cells expressed this antigen
(Fig 4A). However, almost all these cells expressed CD69 when
analysed 1 and 3 days after mitogenic T cell activation (Fig 4A).
Although the T cells analysed on days 1 and 3 after activation
were uniformly positive for CD69 expression, quantification of the
median level of antigen expression per cell demonstrated a marked
reduction between days 1 and 3 after T cell activation (Fig 4B).
The rate of loss of CD69 from the surface of activated T cells
was analysed by fractionating the dividing cells on the basis of
CFSE dilution (Fig 5A). This experiment showed that none of the
cells had divided on day 1, maintaining maximum CD69
expression. However, the overall level of CD69 expression
observed on day 3, for example, was the sum of separate levels
expressed by T cell subpopulations which had divided 0, 1, 2 or 3
times (Fig 5B). On both days 3 and 6 after activation, analysis of
the rate of decrease of CD69 expression between cell cycles 0 and
3 showed a similar half-life of 1.15 and 0.97 mitotic division cycles
respectively (Fig 5C).
Loss of T cell Expression of CD69 Correlates with
Increased S1PR1 Signalling
A series of experiments was performed to demonstrate the
potential to reduce CD69 expression by transfection of resting
human T cells with sequence-specific siRNA sequences prior to
mitogenic activation. After gating to exclude the T cells damaged
during transfection, the percentage of cells expressing CD69 1 day
after mitogenic activation (Fig 6) was reduced from 35.6% (control
siRNA) to 13.6% (CD69-specific siRNA); the corresponding
median fluorescence values were 24.1 and 11.4 respectively.
A series of 3 separate experiments was then performed in which
viable and non-viable T cells were separated after transfection by
fluorescence-activated cell sorting. These cells were then activated
by stimulation of CD3 and CD28 for 1 day and the pAkt/total Akt
ratio was quantified after stimulation with the specific S1PR1
agonist SEW2871. This study demonstrated that treatment with
the CD69-specific siRNA sequence markedly increased the pAkt
signal generated by stimulation of S1PR1 (P,0.001; Fig 7).
Figure 4. Dynamics of CD69 expression following T cell
activation. Resting T cells were loaded with CFSE or not then either
left at rest or stimulated with CD3/CD28 beads for 1, 3 or 6 days. The
cells were then stained with a CD69 monoclonal antibody or with an
isotype-matched control before flow cytometry. (A) Graph showing the
percentage of T cells that were CD69-positive (excess specific staining
over isotype) at each time-point. Data are representative of 2 or 3
independent experiments. (B) Graph showing the median fluorescence
intensity (MFI) of CD69 staining of T cells at each time-point. Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0045548.g004
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Figure 5. Analysis of CD69 expression following T cell mitosis. (A) Two-parameter dot plots showing variation in CD69 expression with
dilution of CFSE during T cell mitosis. Data are representative of two independent experiments. (B) Distinct generations of three-day (black bars) and
six-day (grey bars) activated T cells were identified by their CFSE-mediated fluorescence. The MFI of specific CD69 staining of each group of cells was
calculated by subtracting the median fluorescence intensity associated with the isotype-matched control antibody from that with the monoclonal
antibody against CD69. (C) Natural logarithms of the MFI values were calculated and plotted against the corresponding generation numbers to allow
measurement of the generation half-life of CD69 expression. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0045548.g005
Regulation of S1PR1 Responsiveness by T Cell
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Discussion
The current model for regulation of the egress of T cells from
lymphoid tissue has two facets: the situation in normal circum-
stances and that during non-specific lymph node inflammation.
The current study extends this by using in vivo and in vitro methods
to examine how the exit of antigen-activated T cells from lymph
nodes is controlled.
Published work has shown that the S1P agonist FTY720 can
block the routine efflux of lymphocytes from lymphoid tissue
during homeostasis. However, there has been some debate as to
the extent to which the efflux of activated T cells from lymph
nodes is S1P-dependent. Habicht et al. adoptively transferred
TCR-transgenic, allospecific T cells along with an allograft and
showed that effector memory T cells are trapped in regional
lymphoid tissues by FTY720 treatment [24]. It has been known for
some time that whereas FTY720 treatment efficiently depletes
naı¨ve T cells from peripheral blood, antigen-experienced cells are
not affected [25]. Furthermore, using an in vivo model of contact
hypersensitivity, Nakashima et al. showed that FTY720 did not
significantly suppress the delayed-type hypersensitivity reaction if
administered during the afferent phase [26].
An in vivo model of alloimmunity was used in the current study
to determine whether or not the egress of activated T cells from
lymph nodes is dependent on S1P receptor signalling. The
functional S1P receptor antagonist FTY720-P was administered
two days after sensitisation with allogeneic cells in the foot pad to
minimise unwanted effects on immune priming. This treatment
did not alter the total number of cells within the draining popliteal
node but led to specific accumulation of the subpopulations of
alloreactive and CXCR3-expressing T cells, suggesting that the
ability of activated T cells to exit the reactive node is S1P-
dependent.
Previous work has shown that it is signalling of S1PR1, and not
that of other S1P receptors, that overrides lymph node retention
signals to allow T cell exit from lymph nodes [1]. Regulation of
this receptor following T cell activation was therefore the focus of
the study. The observation that S1PR1 gene expression was
decreased by mitogenic activation of human T cells is consistent
with a previous demonstration that S1PR1 expression is reduced
in mouse T cells following TCR activation [27]. Indeed, it is
known that stimulation through the TCR suppresses expression of
Figure 6. Expression of CD69 expression by activated T cells
transfected with siRNA. Resting T cells were transfected with either
CD69-specific siRNA or negative control siRNA then stimulated with
CD3/CD28 beads for 24 hours. Samples from each cell population were
taken, stained for CD69 (open histogram) or with an isotype control
antibody (grey histogram) and analysed by flow cytometry.
doi:10.1371/journal.pone.0045548.g006
Figure 7. Measurement of Akt phosphorylation following
stimulation of siRNA- transfected T cells with SEW2871. Equal
numbers of the siRNA-transfected, activated T cells were treated with
either 10 mM SEW2871 (+W) or vehicle (-W) for 10 minutes and both
pAkt (serine 473) and total Akt were detected using a cell-based ELISA.
The relative amounts of pAkt in the samples were calculated by
normalising the fluorescent signal value corresponding to pAkt to that
of total Akt in each experimental well. Graph shows means 6 s.e.m. of
triplicate determinations. Data are representative of three independent
experiments.
doi:10.1371/journal.pone.0045548.g007
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the transcription factor KLF2, which is a positive regulator of
S1PR1 transcription [28]. It is interesting that the magnitude of
the signalling response to stimulation of S1PR1 on three-day
activated T cells was comparable to that of resting cells, even
though the gene expression was approximately three-fold lower in
the activated cells. Because of the lack of a monoclonal antibody
which can detect cell-surface S1PR1, the relative amounts of
protein on resting, one day and three day activated cells could not
be directly compared. It also ruled out use of techniques such as
fluorescence resonance energy transfer (FRET) to study directly
protein – protein interactions with S1PR1. Nevertheless, it is
possible to infer from our data that control of S1PR1 gene
expression has only a minor role in the regulation of receptor-
mediated intracellular signalling following T cell activation.
The expression of CD69 on the T cell surface was at a maximal
level 24 h after mitogenic activation. At this time the potential for
agonist-induced S1PR1 signal transduction to elicit phosphoryla-
tion of Akt was completely inhibited. Although most of these T
cells still showed positive cell-surface CD69 after 3 days, the
median level of CD69 expression was greatly reduced. At this time
the cells showed an intracellular signalling response following
stimulation with the S1PR1-specific agonist SEW2871 which was
similar to that of resting T cells. This is consistent with a report
showing that T cells which have been activated in vivo re-acquire at
least some responsiveness to S1P by day 3 [5].
Cell cycle analysis of changes in the cell-surface expression of
CD69 by activated T cells showed that the level of this antigen
decreased by almost exactly one half during each of the first 3 cell
divisions. This is consistent with there being little neosynthesis of
CD69 after the first mitotic division, with the existing protein
dividing equally between the daughter T cells. A previous study
supports this model by demonstrating the mRNA encoding CD69
is only detectable during the first 24 hours after T cell activation
[16]. The current study showed no evidence of T cell proliferation
during this period.
The dilution of CD69 protein during T cell mitosis provides
a potential control mechanism for S1PR1 signalling and is
consistent with an established model [29] in which the division
history of an individual T cell is a major determinant of its fate.
Those T cells that have a short division history would be least
differentiated but, by expressing a high level of CD69 protein,
would be inhibited from exiting the lymph node. In contrast, T
cells that have divided several times would become more
differentiated. These cells would express low levels of CD69
allowing the egress of short-lived effector T cells from the lymph
nodes.
The potential to regulate S1PR1 activity directly by reduction of
the level of CD69 protein expression was examined by transfection
of T cells with specific siRNA sequences prior to mitogenic
activation. The act of transfection of T cells with either control or
CD69-specific siRNA sequences non-specifically prevented a sub-
population of these cells from upregulating CD69 expression
following T cell activation. Nevertheless, stimulation of control
and experimental T cell transfectants with SEW2871 after
mitogenic activation for 24 h revealed a highly significant
difference. In common with non-transfected cells, those T cells
which had received a control siRNA sequence showed no
significant accumulation of pAkt following treatment with the
specific S1PR1 agonist. In contrast, T cells which had been
transfected with the specific siRNA sequence showed a marked
accumulation of pAkt following stimulation with the agonist.
These data suggest that the re-acquisition of responsiveness to
S1PR1 stimulation observed 3 days after T cell activation is
a consequence of the decrease in CD69 expression produced by
between 1 and 3 cycles of mitosis.
The existence of a CD69-mediated mechanism to control
S1PR1 signalling, and therefore by implication to inhibit normal T
cell efflux from lymph nodes, supports the potential for therapeutic
reinforcement of this natural process in order to produce the
depletion of activated allospecific T cells from the circulation of
transplant patients. This provides further impetus for clinical
development of novel immunosuppressive agents which inhibit the
S1P receptor system.
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